Thyroid dysfunction induced by alectinib in a patient with a non-small cell lung cancer
Background: Hypothyroidism is a well-known side effect associated with tyrosine kinase inhibitors (TKIs) therapy. We describe a case of a patient with a history of postsurgical hypothyroidism who presented TSH elevation ranging from 1.68 to 17.09 IU/ml with normal free thyroxine (T4) after starting...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-06-01
|
| Series: | Journal of Clinical and Translational Endocrinology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214624522000077 |
| _version_ | 1818007624109522944 |
|---|---|
| author | L. Plaza-Enriquez M. Sanchez-Valenzuela F. Henriquez |
| author_facet | L. Plaza-Enriquez M. Sanchez-Valenzuela F. Henriquez |
| author_sort | L. Plaza-Enriquez |
| collection | DOAJ |
| description | Background: Hypothyroidism is a well-known side effect associated with tyrosine kinase inhibitors (TKIs) therapy. We describe a case of a patient with a history of postsurgical hypothyroidism who presented TSH elevation ranging from 1.68 to 17.09 IU/ml with normal free thyroxine (T4) after starting treatment with alectinib for non-small cell lung cancer (NSCLC). Case presentation: A 78-year-old female, with past medical history of Graves’ disease with subsequent total thyroidectomy and residual postsurgical hypothyroidism, was diagnosed with non-small cell lung cancer (NSCLC) and presented with TSH elevation with normal free T4 after starting therapy with alectinib. Conclusion: The most likely etiology for TSH elevation during her therapy with alectinib is an increased requirement of thyroid hormone secondary to increase activity of type 3 deiodinase and/or inhibition of monocarboxylate transporter 8 (MCT8) with consequent lower tissue availability of active T3. Further studies of thyroid dysfunction after alectinib administration are lacking. |
| first_indexed | 2024-04-14T05:18:04Z |
| format | Article |
| id | doaj.art-05a7c5251fac4c26affa3b3aa37c494c |
| institution | Directory Open Access Journal |
| issn | 2214-6245 |
| language | English |
| last_indexed | 2024-04-14T05:18:04Z |
| publishDate | 2022-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Clinical and Translational Endocrinology Case Reports |
| spelling | doaj.art-05a7c5251fac4c26affa3b3aa37c494c2022-12-22T02:10:18ZengElsevierJournal of Clinical and Translational Endocrinology Case Reports2214-62452022-06-0124100113Thyroid dysfunction induced by alectinib in a patient with a non-small cell lung cancerL. Plaza-Enriquez0M. Sanchez-Valenzuela1F. Henriquez2Internal Medicine Residency, Memorial Healthcare System, USAInternal Medicine Residency, St. Barnabas Hospital, USA; Corresponding author. 2475 Hughes Ave, Apt 1 C, Bronx, NY, 10458, USA.Endocrinology, Faculty Memorial Healthcare System, Internal Medicine Residency, USABackground: Hypothyroidism is a well-known side effect associated with tyrosine kinase inhibitors (TKIs) therapy. We describe a case of a patient with a history of postsurgical hypothyroidism who presented TSH elevation ranging from 1.68 to 17.09 IU/ml with normal free thyroxine (T4) after starting treatment with alectinib for non-small cell lung cancer (NSCLC). Case presentation: A 78-year-old female, with past medical history of Graves’ disease with subsequent total thyroidectomy and residual postsurgical hypothyroidism, was diagnosed with non-small cell lung cancer (NSCLC) and presented with TSH elevation with normal free T4 after starting therapy with alectinib. Conclusion: The most likely etiology for TSH elevation during her therapy with alectinib is an increased requirement of thyroid hormone secondary to increase activity of type 3 deiodinase and/or inhibition of monocarboxylate transporter 8 (MCT8) with consequent lower tissue availability of active T3. Further studies of thyroid dysfunction after alectinib administration are lacking.http://www.sciencedirect.com/science/article/pii/S2214624522000077Tyrosine kinase inhibitors (TKIs)Thyroid dysfunctionAlectinib |
| spellingShingle | L. Plaza-Enriquez M. Sanchez-Valenzuela F. Henriquez Thyroid dysfunction induced by alectinib in a patient with a non-small cell lung cancer Journal of Clinical and Translational Endocrinology Case Reports Tyrosine kinase inhibitors (TKIs) Thyroid dysfunction Alectinib |
| title | Thyroid dysfunction induced by alectinib in a patient with a non-small cell lung cancer |
| title_full | Thyroid dysfunction induced by alectinib in a patient with a non-small cell lung cancer |
| title_fullStr | Thyroid dysfunction induced by alectinib in a patient with a non-small cell lung cancer |
| title_full_unstemmed | Thyroid dysfunction induced by alectinib in a patient with a non-small cell lung cancer |
| title_short | Thyroid dysfunction induced by alectinib in a patient with a non-small cell lung cancer |
| title_sort | thyroid dysfunction induced by alectinib in a patient with a non small cell lung cancer |
| topic | Tyrosine kinase inhibitors (TKIs) Thyroid dysfunction Alectinib |
| url | http://www.sciencedirect.com/science/article/pii/S2214624522000077 |
| work_keys_str_mv | AT lplazaenriquez thyroiddysfunctioninducedbyalectinibinapatientwithanonsmallcelllungcancer AT msanchezvalenzuela thyroiddysfunctioninducedbyalectinibinapatientwithanonsmallcelllungcancer AT fhenriquez thyroiddysfunctioninducedbyalectinibinapatientwithanonsmallcelllungcancer |